SCHEMBL787106

SCHEMBL787106

C=CCCCCCCCCCCCCCCCCCCN1CCC(C=C)C1=O

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.34
CHRNB2 P17787 1/20 0.31
CHRNA7 P36544 1/20 0.31
CHRNA4 P43681 1/20 0.31
MGLL Q99685 1/20 0.31
CASP3 P42574 1/20 0.31
CASP7 P55210 1/20 0.31
ABCC4 O15439 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
POLB P06746 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922550 1.00 FAAH (0.34) FAAHCHRNB2CHRNA7CHRNA4MGLL
SCHEMBL786721 1.00 FAAH (0.34) FAAHCHRNB2CHRNA7CHRNA4MGLL
SCHEMBL633078 0.93 GBA1 (0.32) KMT2A
SCHEMBL369965 0.86 GBA1 (0.43) FAAHMGLL
SCHEMBL5303207 0.86 GBA1 (0.43) FAAHMGLL
SCHEMBL4282749 0.86 GBA1 (0.43) FAAHMGLL
SCHEMBL2056924 0.86
SCHEMBL7355166 0.78 SMN1; SMN2 (0.32) KMT2A
Water SCHEMBL28388741 0.77 ALDH1A1 (0.33) KMT2A
SCHEMBL7898121 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4616845-A2 SKIN PROTECTANT FILM INCLUDING SKIN HEALTH INGREDIENTS Hollister Incorporated (US) 2025-09-17 EP claimed
US-20240277905-A1 SKIN PROTECTANT FILM INCLUDING SKIN HEALTH INGREDIENTS HOLLISTER INCORPORATED 2024-08-22 US claimed
US-11986574-B2 Skin protectant film including skin health ingredients HOLLISTER INCORPORATED (US) 2024-05-21 US claimed
US-6582683-B2 Of a hydrophilic polymer emulsion and a hydrophobic polymer emulsion; use to protect skin from irritants, chemical or pathogenic SKINVISIBLE PHARMACEUTICALS, INC. 2003-06-24 US claimed
EP-0838498-B1 CARBOXYLATED POLYMER COMPOSITION SUMITOMO SEIKA CHEMICALS (JP) 2002-11-13 EP claimed
US-20020051797-A1 DERMAL BARRIER COMPOSITION SKINVISIBLE PHARMACEUTICALS, INC. 2002-05-02 US claimed
US-6261690-B1 DISPERSION IN HIGH BOILING HEAT EXCHANGE MEDIA AVENTIS RESEARCH & TECHNOLOGY GMBH & CO. KG (DE) 2001-07-17 US claimed
EP-4616845-A2 SKIN PROTECTANT FILM INCLUDING SKIN HEALTH INGREDIENTS Hollister Incorporated (US) 2025-09-17 EP disclosed
CN-120131465-A Oily eyebrow and eye line raincoat capable of prolonging makeup time 浙江睛姿化妆品有限公司 2025-06-13 CN disclosed
US-12195632-B2 Oil-based inkjet ink RISO KAGAKU CORPORATION (JP) 2025-01-14 US disclosed
US-20240277905-A1 SKIN PROTECTANT FILM INCLUDING SKIN HEALTH INGREDIENTS HOLLISTER INCORPORATED 2024-08-22 US disclosed
US-11986574-B2 Skin protectant film including skin health ingredients HOLLISTER INCORPORATED (US) 2024-05-21 US disclosed
WO-2024059862-A2 FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS EVOLVED BY NATURE, INC. (US) 2024-03-21 WO disclosed
WO-2004073644-A2 WATER-SOLUBLE SILK PROTEINS IN COMPOSITIONS FOR SKIN CARE, HAIR CARE OR HAIR COLORING E.I. DUPONT DE NEMOURS AND COMPANY (US) 2004-09-02 WO disclosed
US-20040170590-A1 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring E. I. DU PONT DE NEMOURS AND COMPANY 2004-09-02 US disclosed
US-6582683-B2 Of a hydrophilic polymer emulsion and a hydrophobic polymer emulsion; use to protect skin from irritants, chemical or pathogenic SKINVISIBLE PHARMACEUTICALS, INC. 2003-06-24 US disclosed
US-6497889-B2 CONTAINING HYDROXYPROLINE COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-12-24 US disclosed
US-20020051797-A1 DERMAL BARRIER COMPOSITION SKINVISIBLE PHARMACEUTICALS, INC. 2002-05-02 US disclosed
US-20020009472-A1 Cosmetics KYOWA HAKKO BIO CO., LTD. (JP) 2002-01-24 US disclosed
EP-1166767-A2 Skin care product containing hydroxyproline or N-acylated hydroxyproline derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020051797-A1 DERMAL BARRIER COMPOSITION CUTA, DSG1, POLR1C FAAH 94/4885CHRNB2 4221/4885CHRNA7 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.